Document:

EX-10.28(xvi)

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and
filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

Exhibit 10.28(xvi) 

AMENDMENT NO. 14 TO THE PROCESS DEVELOPMENT
AND CLINICAL SUPPLY AGREEMENT 
 BETWEEN 

FIBROGEN, INC. AND BOEHRINGER INGELHEIM
PHARMA GMBH & CO. KG 
 THIS AMENDMENT NO. 14
(the “Fourteenth Amendment”), effective as of February 5, 2014 (the “Thirteenth Amendment Effective Date”) by and between Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Straße 65, 88397
Biberach an der Riss, Germany (“BI Pharma”) and FibroGen, Inc., 409 Illinois Street, San Francisco, CA 94158, USA (“FibroGen”), amends the Process Development and Clinical Supply Agreement entered into by and between BI
Pharma and FibroGen on November 29, 2007, as amended pursuant to the letter agreements entered into as of June 26, 2008 and August 18, 2008, Amendment No. 1, effective as of May 28, 2009, Amendment No. 3, effective as
of November 5, 2010, Amendment No. 4, effective as of January 24, 2011, Amendment No. 5, effective as of April 15, 2011, Amendment No. 6, effective as of May 26, 2011, Amendment No. 7, effective as of
January 01, 2012, Amendment No. 8, effective as of July 10, 2012, Amendment No. 9, effective as of November 26, 2012, Amendment No. 10, effective as of June 21, 2013, Amendment No. 11, effective as of
July 9, 2013 and Amendment No. 12, effective as of August 1, 2013 (hereinafter together the “Supply Agreement”). BI Pharma and FibroGen shall be referred to individually herein as a “Party”, and collectively as the
“Parties”. 
 WHEREAS, FibroGen wishes BI Pharma to perform [ * ] in compliance with the terms of the
Supply Agreement. 
 NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of
which is hereby acknowledged, the Parties agree as follows: 
  

	 	(1)	Unless otherwise defined herein, all capitalized terms and phrases used in this Fourteenth Amendment shall have the meaning ascribed to them in the Supply Agreement. 

 

	 	(2)	Pursuant to Section 2.2 of the Supply Agreement, Appendix 2 to the Supply Agreement is hereby amended to add the work plan entitled “[ * ], Version of March 4, 2014” attached hereto
as Exhibit A. In accordance with such work plan, BI Pharma shall [ * ] and if FibroGen [ * ], BI Pharma shall [ * ], and [ * ] for FibroGen in accordance with the Supply
Agreement. The Parties agree that the Deliverables to be delivered to FibroGen will include [ * ]. In the event that the Parties agree to [ * ] in the further development of the Product, the terms and conditions for
[ * ] in the course of the Project and any license thereto shall be subject to separate discussion and pursuant to a separate agreement between the Parties. 

 

	 	(3)	This Fourteenth Amendment, together with the Supply Agreement, contains the entire understanding of the Parties with respect to the subject matter hereof. Except as otherwise provided herein, the Supply Agreement has
not been modified or amended and remains in full force and effect. All express or implied agreements and understandings that conflict with the terms of this Fourteenth Amendment, either oral or written, made with respect to the subject matter herein
are expressly superseded by this Fourteenth Amendment. 

  
 1 

					
	Amendment No. 14 to the Process Development and Clinical Supply Agreement	  	 	Confidential	  

  
  

 

	 	(4)	This Fourteenth Amendment may be executed in counterparts, each of which shall be deemed an original, and all of which together shall constitute one and the same instrument. Counterparts may be signed and delivered by
facsimile and/or via portable document format (pdf) (or similar format), each of which shall be binding when sent. 

 IN WITNESS WHEREOF, the
Parties have executed this Fourteenth Amendment to the Supply Agreement as of Fourteenth Amendment Effective Date. 
 Biberach, January 7, 2014 

BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG 

 

							
	 ppa.
	 		  	ppa.	 	
				
	 [ * ]
	 		  	 [ * ]
	 	
	 [ * ]
	 		  	[ * ]	 	
	 VP Business & Contracts
	 		  	Head of Legal Biopharma	 	

 San Francisco, March 11, 2014 

FIBROGEN, INC. 
  

							
	 /s/ Jim Polarek
	 		  	  
	 	
				
	 Name Jim Polarek
	 		  	 Name
	 	
	 Title Vice President
	 		  	 Title
	 	

  

					
		 	2	 	

  
 [ * ] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

					
	Amendment No. 14 to the Process Development and Clinical Supply Agreement	  	 	Confidential	  

  
  

Exhibit A 
 Work
Scope 
 [ * ] 

Version of March 4, 2014 

Please see following page. 

[ * ] 

  

					
		 	3	 	

  
 [ * ] = Certain confidential
information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.EX-10.29

 Exhibit 10.29 
  

 
  

			
		  	225 Gateway Boulevard
	November 3, 2008	  	South San Francisco, CA 94080
		  	Tel. (650) 866-7200
	Frank H. Valone, M.D.	  	Fax (650) 866-7201
	[PRIVATE ADDRESS]	  	

 Dear Frank: 
 FibroGen, Inc. is
pleased to offer you the position of Chief Medical Officer – reporting to Tom Neff, Chief Executive Officer. We are very excited about the possibility of you joining our team, and we look forward to the prospect of working with you in our
innovative company! The following outlines the specific terms of our offer: 
  

	 	•	 	Your salary will be $29,166.67 per month, less taxes and standard deductions as required by law. Paid bimonthly, this figure will annualize to $350,000. 

 

	 	•	 	You will be paid an employment bonus of $30,000, less taxes and standard deductions. 

  

	 	•	 	Pending any necessary approvals, including those of the Company’s Board of Directors, and in compliance with applicable laws and regulations, we plan to offer you an option to purchase 200,000 shares of common
stock of FibroGen, pursuant to the terms and conditions of the Company’s 2005 Stock Plan, and may be amended or modified from time to time. 

  

	 	•	 	You will be eligible for certain FibroGen employee benefits, which will include medical, vision and dental health insurance. Additionally, we offer a 401(k) plan, which provides you with the opportunity for pre-tax
long-term savings by deferring from 1-60% of your annual salary, subject to certain maximums. These benefits may be modified or terminated from time to time, and a benefit summary has been included with this letter. More detailed information
regarding your benefits will be provided at your New Employee Orientation, shortly after you begin employment. 

  

	 	•	 	As a full-time employee, you will receive twenty (20) days of paid vacation each year, which will accrue at the rate of         days per month beginning from your first day
of employment at FibroGen. 

  

	 	•	 	You will abide by FibroGen’s strict company policy that prohibits any new employee from using or bringing with them from any prior employer any proprietary information, trade secrets, proprietary materials or
processes of such former employers. Moreover, because the Company’s proprietary information is extremely important, this offer is expressly subject to your executing the enclosed Confidential Information, Secrecy and Invention Agreement for
Employees. You also agree to follow all other rules and policies that the Company may announce from time to time. 

  

	 	•	 	You will also be required to sign the Employment Eligibility Verification (Form 1-9). (You will need to complete and return Section One of the 1-9 form along with your signed offer letter). On your first day of
employment, please bring the necessary documents that establish your identity and employment eligibility. Acceptable documents are listed on the reverse side of the I-9 form. Such documentation must be provided to us within three
(3) business days of your date of hire, or our employment relationship with you may be terminated 

 Valone, Frank 

 Page
 2
 
  

	 	•	 	You should be aware that your employment with the Company is for no specified period and constitutes “at-will” employment. As a result, you are free to resign at
any time, for any reason, with or without cause or notice. Similarly, the Company is free to conclude its employment with you at any time. The changing needs of the Company could also result in changes to certain aspects of
your employment, such as compensation, responsibilities, location, etc. These provisions expressly supersede any previous representations, oral or written. Your at-will employment cannot be modified or amended except by written agreement signed by
both you and the President of the Company. 

  

	 	•	 	Any dispute or claim, including all contract, tort, discrimination and other statutory claims, arising under or relating to your employment or termination of your employment with the Company but excepting claims under
applicable workers’ compensation law and unemployment insurance claims (“arbitrable claims”) alleged against the Company and/or its agents shall be resolved by arbitration. However, you and the Company agree that this arbitration
provision shall not apply to any disputes or claims relating to or arising out of the misuse or misappropriation of the Company’s trade secrets. Such arbitration shall be final and binding on the parties and shall be the exclusive remedy for
arbitrable claims. You and the Company hereby waive any rights each may have to a jury trial in regard to the arbitrable claims. Arbitration shall be conducted by the American Arbitration Association in San Mateo (or other mutually
agreed upon city) under the National Rules for the Resolution of Employment Disputes. In any arbitration, the burden of proof shall be allocated as provided by applicable law. The Company agrees to pay the fees and costs of the
arbitrator. However, the arbitrator shall have the same authority as a court to award equitable relief, damages, costs, and fees (excluding the costs and fees for the arbitrator) as provided by law for the particular claims asserted.

 Unless otherwise notified by the Company, this offer of employment is effective for 5 business days from the date of this letter.
There are two originals of this letter enclosed. If all of the foregoing is satisfactory, please sign and date each original and return one to me within five business days in the enclosed envelope, saving the other original for yourself. Please also
complete the following enclosed forms and mail them back with your signed offer letter: 
  

	•	 	I-9 Form 

  

	•	 	Confidential Information, Secrecy and Invention Agreement 

  

	•	 	FibroGen Employment Application 

 Frank, we look forward to your joining our team at FibroGen. 

 

	
	Sincerely,
	
	 /s/ Ted A. Tucker

	Ted A. Tucker
	Vice President, Human Resources

 Valone, Frank 

 Page
 3
 
  

	
	ACCEPTED AND AGREED TO this
	
	5th Day of November, 2008
	
	 /s/ Frank H. Valone

	Frank H. Valone, M.D.
	
	 December 1, 2008

	Intended Start Date

  

			
	Enclosures:	  	 Benefits Summary
 Duplicate Letter

Return Envelope
 Employment Eligibility Verification (I-9)
Form
 Confidential Information, Secrecy and Invention Agreement

FibroGen Employment Application

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00236-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00236-of-00352.parquet"}]]